GEn1E Lifesciences

GEn1E Lifesciences operates as a clinical-stage, multi-target pharmaceutical company distinguished by its proprietary AI platform. The company focuses on developing innovative, next-generation immunomodulatory therapies for rare and inflammatory diseases where effective treatments are currently lacking. By applying artificial intelligence to multi-mechanism-of-action protein targets, GEn1E aims to significantly accelerate the drug development process, creating novel therapeutics at an unprecedented pace. Their AI platform has already facilitated the development of a targeted therapy for Acute Respiratory Distress Syndrome (ARDS), with the potential to substantially reduce its considerable societal cost.

GEn1E has cultivated a robust pipeline of over 21 novel and selective immunomodulators and plans to advance therapies for two additional severe diseases to Investigational New Drug (IND) status within the next year. The AI platform enables exceptional speed and capital efficiency, as evidenced by the company's progress in approximately two years with seed funding—a marked contrast to the typical expenditure of over $100 million and a development timeline of seven years or more within the broader pharmaceutical and biotechnology sectors.

Addressing the significant unmet need in rare diseases, where approximately 90% lack any therapeutic treatment, GEn1E Lifesciences is committed to developing potentially life-saving therapies for patients in need. The company's team possesses extensive experience in both drug development and machine learning. GEn1E Lifesciences is based in Palo Alto, CA, and is an alumnus of Y Combinator and Stanford-StartX (2019).